Similarly, Paricalcitol showed relevant beneficial effects in the alleviation of liver fibrosis (Reiter et al., 2019), peritoneal fibrosis (Ko et al., 2019), and myocardial fibrosis (Panizo et al., 2013) by blocking the TGF-β pathway. Here, TGFB1 is linked to Hepatic fibrosis.